| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 09/12/2023 | 170.27% | Maxim Group | → $10 | Initiates Coverage On | → Buy |
| 08/31/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 08/14/2023 | 62.16% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 08/14/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/12/2023 | 170.27% | Oppenheimer | → $10 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/15/2023 | 62.16% | Chardan Capital | $5.75 → $6 | Maintains | Buy |
| 05/01/2023 | 170.27% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/27/2023 | 55.41% | Chardan Capital | $4 → $5.75 | Maintains | Buy |
| 12/09/2022 | 8.11% | Chardan Capital | → $4 | Initiates Coverage On | → Buy |
| 11/25/2022 | 170.27% | Oppenheimer | $30 → $10 | Maintains | Outperform |
| 11/14/2022 | 170.27% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 11/14/2022 | 170.27% | BTIG | $30 → $10 | Maintains | Buy |
| 08/19/2022 | 35.14% | B. Riley Securities | $11 → $5 | Downgrades | Buy → Neutral |
| 03/29/2022 | 332.43% | B. Riley Securities | $21 → $16 | Maintains | Buy |
| 03/29/2022 | 224.32% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 11/03/2021 | 467.57% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 04/12/2021 | 710.81% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
| 04/12/2021 | 710.81% | BTIG | → $30 | Initiates Coverage On | → Buy |
What is the target price for Gain Therapeutics (GANX)?
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $10.00 expecting GANX to rise to within 12 months (a possible 170.27% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gain Therapeutics (GANX)?
The latest analyst rating for Gain Therapeutics (NASDAQ: GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
Is the Analyst Rating Gain Therapeutics (GANX) correct?
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Gain Therapeutics (GANX) is trading at is $3.70, which is within the analyst's predicted range.